The global Central Venous Access Devices market was valued at USD 2,110 Million in 2025, and it is projected to reach USD 4,080 Million by 2035, growing at a CAGR of 6.8% from 2024 to 2035. This report offers a detailed analysis of market drivers, trends, opportunities, revenue forecasts, regional shares, and recent developments shaping the landscape of central venous access devices globally.
The economic impact of tariffs on "Global Central Venous Access Devices".
Market Growth Drivers
Rising incidences of chronic diseases such as cancer and end-stage renal disease are fueling the demand for central venous access devices. Companies like Becton, Dickinson and Company (BD) are expanding their product portfolio to cater to the growing need for safe and efficient long-term vascular access for administration of chemotherapy, antibiotics, and parenteral nutrition.
Technological advancements in device design, such as antimicrobial and antithrombogenic coatings, are enhancing patient outcomes. Teleflex Incorporated recently launched innovative catheters with advanced safety features that reduce the risk of bloodstream infections and thrombosis, thereby driving market adoption.
Market Trends
The adoption of minimally invasive procedures is becoming increasingly prevalent, driving demand for central venous access devices that ensure quicker recovery and lower infection risks. Companies like B. Braun Melsungen AG are introducing user-friendly peripherally inserted central catheters (PICCs) that minimize procedural complications.
There is a growing emphasis on single-use and disposable catheters in response to heightened awareness regarding hospital-acquired infections. Leading manufacturers such as Smiths Medical are focusing on eco-friendly, disposable central venous catheters, aligning with sustainability trends and regulatory expectations.
Market Opportunities
Significant growth potential exists in emerging markets like India, Brazil, and Southeast Asia, where expanding healthcare infrastructure and rising awareness are increasing the adoption of advanced central venous access devices. Companies like AngioDynamics are actively entering these regions through strategic partnerships.
The increasing utilization of central venous access devices in home-care settings, especially for long-term therapies, presents a lucrative opportunity. Teleflex is investing in patient-centric solutions that make self-administration of intravenous therapy more accessible and safer.
Global Central Venous Access Devices Market Revenue (USD Million), 2020-2035
The revenue chart illustrates steady and sustained growth in the Central Venous Access Devices market from 2020 to 2035. Starting from USD 1,320 Million in 2020, the market demonstrates accelerated growth after 2024, fueled by rising chronic disease cases, technological innovations, and an expanding aging population. By 2025, revenue hits USD 2,110 Million, and robust adoption continues to propel the market to USD 4,080 Million by 2035. This positive trajectory underscores the impact of improved health awareness, government investments, and the introduction of new, patient-friendly devices.
Global Central Venous Access Devices Market Share by Region (%), 2025
According to 2025 estimates, North America leads the Central Venous Access Devices market with a dominant 39% share, driven by advanced healthcare infrastructure, high disease prevalence, and strong manufacturer presence. Europe holds a significant 27% market share, attributed to rising geriatric populations and growing adoption of innovative devices. Asia-Pacific is emerging rapidly, capturing 22% of the market due to increasing healthcare investments. Latin America and Middle East & Africa account for 7% and 5%, respectively, reflecting gradual improvements in hospital care and awareness.
Recent Developments in Central Venous Access Devices
In March 2024, Becton, Dickinson and Company (BD) received FDA clearance for its next-generation PowerGlide Pro™ Short Peripheral Catheter, which now incorporates antimicrobial protection and extended dwell capability. BD claims this device will lower infection rates and improve patient comfort during longer hospital stays.
In April 2024, Teleflex Incorporated announced the launch of the Arrow® ErgoPack® Complete System, designed to streamline central venous catheter insertion and reduce time-to-treatment in critical care settings. This integrated solution facilitates workflow efficiency and aligns with current best practices in infection control.
May 2024 saw Smiths Medical expand its Jelco® Safety Catheter range with advanced blood control technology. This release emphasizes both staff and patient safety, reducing the risk of occupational exposure and ensuring compliance with evolving healthcare safety regulations.
North America, Europe, Asia-Pacific, South America, Middle East, Africa
Segments
By Type: Peripherally Inserted Central Catheters (PICC), Centrally Inserted Central Catheters, Implanted Ports, Tunneled Catheters, Non-tunneled Catheters, Other Types; By Application: Chemotherapy, Drug Administration, Fluid and Nutrition Administration, Blood Transfusion, Diagnostics & Testing, Other Applications
Press Releases